185 related articles for article (PubMed ID: 24812044)
21. [A possible effect of the immunomodulating therapy with beta-interferons and glatimer acetate on the development of thyroid disease in patients with multiple sclerosis].
Petrova LV; Boĭkova AN; Batysheva TT; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):58-67. PubMed ID: 21916158
[TBL] [Abstract][Full Text] [Related]
22. Relations between mood characteristics, circadian preferences, and functionality in multiple sclerosis.
Ozdemir PG; Milanlioglu A; Boysan M; Cilingir V; Aydin N; Atli A
Int J Psychiatry Clin Pract; 2015 Jun; 19(2):148-54. PubMed ID: 25363199
[TBL] [Abstract][Full Text] [Related]
23. Disease modifying treatment in multiple sclerosis.
Fuller GN; Bone I
J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
[No Abstract] [Full Text] [Related]
24. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
[No Abstract] [Full Text] [Related]
25. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
[TBL] [Abstract][Full Text] [Related]
27. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
28. Multiple Sclerosis.
Reich DS; Lucchinetti CF; Calabresi PA
N Engl J Med; 2018 Jan; 378(2):169-180. PubMed ID: 29320652
[No Abstract] [Full Text] [Related]
29. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
Río J; Ruiz-Peña JL
J Neurol Sci; 2016 Feb; 361():158-67. PubMed ID: 26810535
[TBL] [Abstract][Full Text] [Related]
30. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
[TBL] [Abstract][Full Text] [Related]
31. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA;
Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507
[TBL] [Abstract][Full Text] [Related]
32. [Changes in quality of life in patients with remitted multiple sclerosis during the specific treatment with disease-modifying drugs: a comparative study of populations of Moscow and Novosibirsk].
Popova EV; Riabukhina OV; Vorob'eva OV; Malkova NA; Boĭko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):67-70. PubMed ID: 21322129
[No Abstract] [Full Text] [Related]
33. [Multiple sclerosis: current therapies and future perspectives].
Matsushita T
Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
[TBL] [Abstract][Full Text] [Related]
35. Glatiramer and suspected multiple sclerosis. No proven advantage.
Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
[No Abstract] [Full Text] [Related]
36. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
37. Multiple sclerosis: monotherapy rules.
Hauser SL; Josephson SA; Johnston SC
Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
[No Abstract] [Full Text] [Related]
38. Editorial: the pitfalls of combination therapy.
Vermersch P
Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
[No Abstract] [Full Text] [Related]
39. Effects of multiple sclerosis and medications on menopausal age.
Türk Börü Ü; Köseoğlu Toksoy C; Bölük C; Bilgiç A; Taşdemir M
J Int Med Res; 2018 Mar; 46(3):1249-1253. PubMed ID: 29332426
[TBL] [Abstract][Full Text] [Related]
40. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
Bourdette D; Hartung D
JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
